Nursing care
Glycoprotein IIb/IIIa inhibitors: bleeding, access sites and platelet checks
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated October 2026
Short answer
Glycoprotein IIb/IIIa inhibitors such as eptifibatide and tirofiban are intravenous antiplatelet drugs used short term in acute coronary syndrome and coronary intervention. They block the final step of platelet aggregation, so bleeding is the main risk. Nurses check access sites, limit punctures, trend haemoglobin and platelets, and stop the infusion for profound thrombocytopenia under protocol.
Blocking the final common pathway of platelet aggregation
Platelets link to each other through fibrinogen bridges between glycoprotein IIb/IIIa receptors. These drugs occupy that receptor, so platelets activated by any trigger cannot aggregate. Because they are given only intravenously, they are used for short periods, usually with heparin and oral antiplatelet therapy, around percutaneous coronary intervention or in high-risk acute coronary syndrome.
This powerful effect explains the nursing focus. Anything that breaks the skin or mucosa can bleed, and the drug is often running alongside an anticoagulant. Contraindications on the eptifibatide label include recent abnormal bleeding, recent stroke or any haemorrhagic stroke, recent major surgery, severe uncontrolled hypertension, dialysis dependence and concurrent use of another drug in this class.
Bleeding and access-site surveillance
Check the femoral or radial access site, distal pulses and the area around it frequently, looking for oozing, a haematoma, swelling or a change in limb colour. Back, flank or groin pain with falling blood pressure can signal retroperitoneal bleeding. Also watch for gum bleeding, haematuria, blood in stool or emesis and any new neurological change.
Minimise arterial and venous punctures, intramuscular injections, urinary catheters and nasogastric tubes while the infusion runs, and avoid non-compressible sites. Sheath removal follows a protocol that includes stopping heparin and checking coagulation results first. If major bleeding occurs, stop the infusion, apply pressure where possible, assess haemodynamic status and escalate urgently.
Thrombocytopenia, kidneys and laboratory monitoring
Before the infusion, baseline haemoglobin or haematocrit, platelet count, creatinine and clotting studies help identify existing problems. Acute, profound thrombocytopenia has been reported with eptifibatide. A sudden platelet fall, particularly to the threshold set in the label, calls for stopping the drug and heparin, notifying the prescriber and repeating counts.
Eptifibatide is substantially cleared by the kidneys, so the infusion rate is reduced in renal impairment; the nurse checks that the order reflects current kidney function rather than calculating a change independently. A falling haemoglobin without visible blood loss deserves the same attention as an obvious bleed, because internal bleeding may be the cause.
Handover, timing and coordination with the cardiac team
These infusions usually follow a set duration after the procedure, so handover should state the start time, planned stop time, the concurrent anticoagulant and the most recent platelet count and haemoglobin. Confirm whether the access sheath is still in place and what the protocol requires before it is removed or the patient mobilises.
Report any new chest pain, ECG change or sudden shortness of breath, because recurrent ischaemia and bleeding can both present after intervention. Ask the prescriber before giving additional anticoagulant or antiplatelet doses, and check whether planned procedures such as central line insertion can wait until the infusion has finished and its effect has faded.
An original scenario to test the priority
Imagine a hypothetical patient on an eptifibatide infusion after coronary stenting who now has a platelet count far below his baseline and new petechiae. The options are to continue the infusion and recheck tomorrow, give the scheduled intramuscular vaccine, or stop the infusion per protocol and notify the prescriber. Stopping and notifying is correct because profound thrombocytopenia raises bleeding risk. An intramuscular injection would add a bleeding site, and waiting until tomorrow delays action on a finding the label treats as a reason to stop. Document the count, the skin findings and the time the prescriber was informed.
Teaching is brief because the drug is short term, but patients should know why they must keep the affected limb straight after femoral access, why they must report warmth, wetness or pain at the site, and why they should use a soft toothbrush and electric razor while on the infusion.
Sources and further reading
StatPearls: Antiplatelet Medications. Mechanism of glycoprotein IIb/IIIa inhibitors, intravenous short-term use in ACS, bleeding and thrombocytopenia.
DailyMed: Eptifibatide injection prescribing information. Contraindications, renal dose adjustment, access-site and puncture precautions, baseline labs and thrombocytopenia action.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our cardiovascular practice questions are the closest set to what this page covers.
Common questions
Are glycoprotein IIb/IIIa inhibitors the same as anticoagulants?
No. They are antiplatelet drugs that block platelet aggregation. They are often given with heparin, so bleeding risk reflects the combination.
What finding should make the nurse stop the infusion?
Major bleeding or an acute, profound fall in platelet count are reasons to stop the infusion per protocol and notify the prescriber urgently.
Why does kidney function matter with eptifibatide?
Eptifibatide is largely cleared by the kidneys, so impaired function raises drug levels and bleeding risk. The infusion rate is adjusted by the prescriber accordingly.
More on cardiovascular
Guides on this